Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.
As the 2019 National HIV Prevention Conference kicked off on March 18, plenary speakers discussed not only recent biomedical advances, but also what is truly needed in heavily affected U.S. communities to end the epidemic.
"We don't need to spend another $140 million to find out how to retain people in care," activist David Barr writes. "We need to invest in the kinds of services people need so that they can use treatment easily and effectively."
Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.
The global increase in sexually transmitted infections was a major focus of the CROI 2019 meeting in Seattle, Washington.
This study identified some information about transgender women's sexual networks in Los Angeles. But activists worry about privacy and the potential that the surveillance method will be used in HIV criminalization cases.
Some have expressed concern that, as PrEP use increases in the U.S., so will the transmission of other STIs. A new study pushes back against that worry.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
Sexually transmitted infections are on the rise in the U.S. A recent study explored whether chlamydia and gonorrhea infections have a direct relationship to HIV rates and, if so, how large the impact is.
Although the move means that more Britons might be able to access free PrEP, this study is also controversial for being seen as a way to delay full government approval.